tiprankstipranks
Ocugen: FDA agrees to control, design for Phase 3 study of NeoCart
The Fly

Ocugen: FDA agrees to control, design for Phase 3 study of NeoCart

Ocugen announced that the U.S. FDA agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults. The Phase 3 study will be a randomized, controlled trial to demonstrate the superiority over standard of care, chondroplasty, in subjects with articular cartilage defects. Ocugen plans to enroll subjects with one or two articular cartilage lesions with a total surface area of 1-3 cm. Ocugen is building a current Good Manufacturing Practice cell therapy manufacturing facility to support establishment of the clinical and commercial manufacturing process for NeoCart. The company plans to file an Investigational New Drug amendment to initiate a Phase 3 clinical trial in late 2023/early 2024.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on OCGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles